ATLANTA - Ruxolitinib reduces splenomegaly and other symptoms commonly associated with myelofibrosis, and the results are maintained for at least two years, according to results released at the 54th American Society of Hematology Annual Meeting... via Featured Health News from Medical News Today Read More Here..
No comments:
Post a Comment